Curium SAS (Curium Pharma), and H.I.G. Capital, LLC are among suitors shortlisted in the bidding for Cardinal Health, Inc. (NYSE:CAH)'s nuclear medicine business, people familiar with the matter said. Cardinal has invited the remaining bidders to submit final offers by mid-May, the people said, asking not to be identified as the matter is private. A deal could value the business at about $2 billion or more, according to the people.

Bloomberg News first reported in March that Cardinal was weighing a potential sale of the nuclear medicine business. Cardinal said in September it would review its strategy, portfolio, capital-allocation plans and operations after activist investor Elliott Investment Management took a stake in the company. The unit makes radioactive agents and drugs that doctors use to diagnose and treat diseases like cancer.

Deliberations are ongoing, and there's no certainty the suitors will proceed with final bids, the people said. Representatives Cardinal, Curium and HIG declined to comment.